Dissolution Testing of new and special Dosage Forms - Updated FIP/AAPS Document
Recommendation
Tuesday, 4 February 2025 9 .00 - 17.00 h
Establishment, Use and Maintenance of Analytical Reference Substances
In 2003, the FIP Dissolution Working group published a position paper on dissolution/drug release testing for special and novel dosage forms that represented the scientific knowledge in the field at that time. This position paper from 2003 has given impetus in the scientific, technical, and regulatory community.
Due to the rapid evolution of new practices and techniques for dissolution/drug release testing, the FIP Special Interest Group on Dissolution/Drug Release decided to revise the previous paper.
In the recently presented Workshop Report the following dosage forms are discussed:
- Conventional solid drug products
- Oral suspensions
- Orally disintegrating tablets
- Chewable tablets
- Powders and granules
- Thin dissolvable films
- Chewing gums
- Dermal systems (patches)
- Topical systems (semisolid dosage forms)
- Suppositories
- Microparticulate formulations
- Implants
- Aerosols
Please find the extensive Report at "FIP/AAPS Joint Workshop Report: Dissolution/In Vitro Release Testing of Novel/Special Dosage Forms".
Author:
Dr. Günter Brendelberger
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
15.01.2025English Translation of Supplement II to the Japanese Pharmacopoeia (JP18) Published
08.01.2025EDQM publishes new FAQ on System Suitability Test (SST)
08.01.2025Pharmeuropa Chapter 2.1.7. Balances for Analytical Purposes published for Comments
08.01.2025How to Guarantee a Complete FDA Inspection Failure
11.12.2024Another FDA Warning Letter Based on Review of Records